ELV:NYE-Elevance Health Inc (USD)

COMMON STOCK | Healthcare Plans |

Last Closing

USD 534.81

Change

0.00 (0.00)%

Market Cap

USD 125.26B

Volume

0.58M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-15 )

Largest Industry Peers for Healthcare Plans

Symbol Name Price(Change) Market Cap
UNH UnitedHealth Group Incorporate..

+1.78 (+0.31%)

USD 532.88B
CNC Centene Corp

-0.95 (-1.26%)

USD 39.78B
MOH Molina Healthcare Inc

-1.69 (-0.49%)

USD 20.81B
OSCR Oscar Health Inc

-0.62 (-2.78%)

USD 5.30B
NEUE NeueHealth Inc

-0.02 (-0.39%)

USD 0.05B
CI Cigna Corp

-1.77 (-0.50%)

N/A
CVS CVS Health Corp

+0.51 (+0.89%)

N/A
HUM Humana Inc

-0.54 (-0.17%)

N/A

ETFs Containing ELV

ZWHC:CA BMO Covered Call Health C.. 4.88 % 0.00 %

N/A

N/A
DBPD:XETRA Xtrackers ShortDAX x2 Dai.. 4.88 % 0.00 %

-0.01 (0.21%)

USD 0.13B
HHL-U:CA Harvest Healthcare Leader.. 4.80 % 0.00 %

-0.03 (0.21%)

N/A
HHL-B:CA Harvest Healthcare Leader.. 4.80 % 0.00 %

N/A

N/A
WHCS:SW iShares MSCI World Health.. 3.67 % 0.00 %

N/A

N/A
CBUF:XETRA iShares MSCI World Health.. 3.48 % 0.00 %

-0.04 (0.21%)

USD 1.13B
CBUF:F iShares V Public Limited .. 3.37 % 0.00 %

-0.04 (0.21%)

N/A
PBI:CA Purpose Best Ideas 3.29 % 0.79 %

-0.10 (0.21%)

CAD 0.01B
AILV 3.21 % 0.00 %

N/A

N/A
ESGI:AU VanEck MSCI International.. 2.62 % 0.00 %

-0.13 (0.21%)

USD 0.19B
WELG:XETRA Amundi S&P Global Health .. 2.53 % 0.00 %

-0.03 (0.21%)

N/A
WELS:XETRA Amundi S&P Global Health .. 2.53 % 0.00 %

-0.04 (0.21%)

N/A
UBUS:F UBS (Irl) ETF Public Limi.. 2.21 % 0.00 %

+0.07 (+0.21%)

USD 0.18B
UBUW:F UBS (Irl) ETF Public Limi.. 2.21 % 0.00 %

+0.13 (+0.21%)

USD 0.02B
UBUS:XETRA UBS (Irl) ETF plc - Facto.. 2.21 % 0.00 %

+0.03 (+0.21%)

USD 0.49B
UBUW:XETRA UBS (Irl) ETF plc - Facto.. 2.21 % 0.00 %

+0.11 (+0.21%)

USD 0.05B
UPVLE:SW UBS (Irl) ETF plc - Facto.. 2.21 % 0.00 %

N/A

USD 0.02B
UPVLD:SW UBS (Irl) ETF plc - Facto.. 2.21 % 0.00 %

+0.03 (+0.21%)

USD 0.18B
UPVLH:SW UBS (Irl) ETF plc - Facto.. 2.21 % 0.00 %

N/A

USD 8.41M
H41D:XETRA HSBC MSCI World Value ESG.. 2.16 % 0.00 %

+0.05 (+0.21%)

N/A
HWVS:LSE HSBC MSCI World Value ESG.. 2.02 % 0.00 %

+0.03 (+0.21%)

USD 0.22B
XWEB:XETRA Xtrackers MSCI World Mini.. 1.61 % 0.00 %

-0.11 (0.21%)

USD 0.02B
WCEO Hypatia Women Ceo ETF 1.05 % 0.00 %

+0.08 (+0.21%)

USD 3.52M
PYF-B:CA Purpose Fund Corp. - Purp.. 0.74 % 0.00 %

N/A

N/A
PYF-U:CA Purpose Fund Corp. - Purp.. 0.74 % 0.00 %

N/A

N/A
IHF iShares U.S. Healthcare P.. 0.00 % 0.43 %

-0.19 (0.21%)

N/A
RYH 0.00 % 0.40 %

N/A

N/A
UC96:LSE UBS (Irl) ETF plc - Facto.. 0.00 % 0.00 %

N/A

USD 0.17B
UPVL:LSE UBS (Irl) ETF plc - Facto.. 0.00 % 0.00 %

+5.50 (+0.21%)

USD 8.30M
XSD2:LSE db x-trackers ShortDAX x2.. 0.00 % 0.00 %

-1.21 (0.21%)

USD 0.14B
PBI-B:CA Purpose Fund Corp. - Purp.. 0.00 % 0.00 %

N/A

N/A
TEQI T. Rowe Price Equity Inco.. 0.00 % 0.00 %

-0.04 (0.21%)

USD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (Healthcare Plans) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.41% 88% B+ 84% B
Dividend Return 0.69% 60% D- 28% F
Total Return 14.10% 88% B+ 83% B
Trailing 12 Months  
Capital Gain 20.67% 75% C 81% B-
Dividend Return 1.40% 60% D- 20% F
Total Return 22.07% 75% C 79% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.16% 13% F 42% F
Dividend Return 0.63% 13% F 32% F
Total Return 0.47% 20% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 7.05% 100% F 84% B
Risk Adjusted Return 8.98% 13% F 35% F
Market Capitalization 125.26B 89% A- 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.